Overview

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.

Phase:

Phase 2

Details

Lead Sponsor:

Swedish Orphan Biovitrum

Collaborator:

Amgen

Treatments:

Methotrexate